Abstract
We report a case of reactive arthritis (ReA) during induction phase chemotherapy of
a 15-year-old male patient with acute myeloid leukemia (AML) M4 with inv(16), most
probably due to a genetic predisposition of being human leukocyte antigen b27 (HLA-B27)
positive. The episode of ReA recurred during consolidation therapy; however, the patient
was asymptomatic after the completion of treatment. The link between HLA-B27 and a
large family of inflammatory rheumatic diseases is a well-established fact, but interestingly,
there is also a molecular link between HLA-B27 and hematological malignancies. This
case brings to our notice, the common immunological, molecular, and microbiological
link between AML, HLA-B27, and ReA. It also emphasizes the fact that clinicians should
have a high index of suspicion of HLA-B27 positivity, if a case of AML develops arthritis
during chemotherapy, since early introduction of immunosuppressive medications for
arthritis may reduce morbidity and prevent delay in the administration of further
chemotherapy cycles.
Keywords
Acute myeloid leukemia - arthritis - human leukocyte antigen B27